Try our beta test site

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 15, 2006
Last updated: October 28, 2010
Last verified: June 2009

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Phenoxodiol may help docetaxel work better by making tumor cells more sensitive to the drug.

PURPOSE: This randomized phase I/II trial is studying the side effects of docetaxel when given together with either phenoxodiol or placebo and to see how well it works in treating patients with recurrent advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Condition Intervention Phase
Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
Drug: docetaxel
Drug: idronoxil
Other: placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination With Docetaxel Versus Docetaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Survival (progression-free/recurrence-free interval and overall survival)
  • Tumor response as assessed by RECIST criteria and clinical examination
  • Changes in tumor marker CA125 as assessed by Rustin criteria
  • Safety

Estimated Enrollment: 60
Study Start Date: April 2006
Estimated Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
Drug: docetaxel
Given IV
Other: placebo
Given orally
Experimental: Arm II
Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
Drug: docetaxel
Given IV
Drug: idronoxil
Given orally

Detailed Description:



  • Determine the safety and tolerability of combination therapy comprising phenoxodiol and docetaxel in patients with recurrent or persistent advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.


  • Determine the effect of phenoxodiol on the toxicity of docetaxel using a weekly treatment regimen.
  • Determine if combination therapy comprising phenoxodiol and docetaxel is more efficacious than docetaxel therapy alone.
  • Determine if combination therapy comprising phenoxodiol and docetaxel affects blood levels of either drug.
  • Determine phenotypic differences in the tumor cells of "responders" and "non-responders."

OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
  • Arm II: Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel as in arm I.

Treatment in both arms repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed monthly for 6 months, every 3 months for 1 year, and then annually thereafter.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed diagnosis of 1 of the following:

    • Ovarian epithelial cancer
    • Fallopian tube cancer
    • Primary peritoneal cavity cancer
  • Recurrent advanced disease

    • Eligible for second-line to fifth-line chemotherapy
    • Received platinum and taxane combination chemotherapy as first-line treatment with disease recurrence > 6 months after conclusion of therapy

      • No demonstrated refractoriness or resistance to weekly docetaxel
  • Meets 1 of the following criteria:

    • Doubling of blood levels of CA125 in the past 6 months and CA125 levels ≥ 2 times upper limit of normal (ULN)
    • Measurable disease defined as ≥ 1 lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
  • No active CNS metastases

    • Prior CNS metastases allowed provided they were treated with radiation therapy and disease has been stable for 4 weeks


  • Karnofsky performance score ≥ 60%
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after completion of study treatment
  • Life expectancy ≥ 3 months
  • Creatinine ≤ 1.5 mg/dL
  • Transaminases ≤ 3 times upper limit of normal (ULN)
  • Bilirubin normal
  • Platelet count > 100,000/mm^3
  • WBC > 3,000/mm^3
  • Neutrophil count > 1,500/mm^3
  • Hemoglobin ≥ 8.0 g/dL
  • Peripheral neuropathy ≤ grade 1
  • Relative proportions of AST, ALT, and alkaline phosphatase according 1 to the following criteria:

    • Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times ULN
    • AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN
    • AP ≤ 5 times ULN AND AST/ALT normal
  • No active infection
  • No concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, hypertension, ischemic heart disease, or congestive heart failure)
  • No history of chronic active hepatitis or cirrhosis
  • No history of severe hypersensitivity to docetaxel or other drugs formulated with polysorbate 80


  • See Disease Characteristics
  • No investigational agents within 4 weeks prior to study entry
  • Recovered from prior antineoplastic therapy
  • No other concurrent investigational drugs
  • No other concurrent chemotherapy, radiotherapy, immunotherapy, or hormonal antitumor therapy

    • Concurrent localized radiation therapy allowed for control of local disease complications (e.g., bone metastases) that do not represent a general progression of the disease status
  • No concurrent grapefruit or grapefruit juice
  • No concurrent amifostine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00303888

United States, Connecticut
Yale Cancer Center Recruiting
New Haven, Connecticut, United States, 06520-8028
Contact: Clinical Trials Office - Yale Cancer Center    203-785-5702      
Sponsors and Collaborators
Yale University
National Cancer Institute (NCI)
Principal Investigator: Thomas J. Rutherford, MD, PhD Yale University
  More Information Identifier: NCT00303888     History of Changes
Other Study ID Numbers: CDR0000462103
Study First Received: March 15, 2006
Last Updated: October 28, 2010

Keywords provided by National Cancer Institute (NCI):
recurrent ovarian epithelial cancer
fallopian tube cancer
peritoneal cavity cancer
stage III ovarian epithelial cancer
stage IV ovarian epithelial cancer

Additional relevant MeSH terms:
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on March 27, 2017